|
1
|
Peng SP, Fang WY, Dai WJ, Zou XQ, Liu HY
and Cao JG: Cloning expression and space conformation analysis of
vascular basement membrane-derived multifunctional peptide. Chinese
J Cancer Biother. 10:185–189. 2003.
|
|
2
|
Peng SP, Fang WY, Jiang RC, Zhou JG and
Cao JG: Prokaryotic expression of vascular basement
membrane-derived multi-functional peptide and its anti-tumor
activity assay. Zhongguo Yaolixue Tongbao. 19:678–682. 2003.
|
|
3
|
Cao JG, Peng SP, Sun L, Li H, Wang L and
Deng HW: Vascular basement membrane-derived multifunctional
peptide, a novel inhibitor of angiogenesis and tumor growth. Acta
Biochim Biophys Sin (Shanghai). 38:514–521. 2006. View Article : Google Scholar
|
|
4
|
Wang C, Cao J, Qu J, Li Y, Peng B, Gu Y
and He Z: Recombinant vascular basement membrane derived
multifunctional peptide blocks endothelial cell angiogenesis and
neovascularization. J Cell Biochem. 111:453–460. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View
Article : Google Scholar
|
|
6
|
Long QZ, Zhou M, Liu XG, Du YF, Fan JH, Li
X and He DL: Interaction of CCN1 with αvβ3 integrin induces
P-glycoprotein and confers vinblastine resistance in renal cell
carcinoma cells. Anticancer Drugs. 24:810–817. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang CK, Cao JG, Peng B, Gu YX, Zheng GP
and He ZM: Inhibition of growth and motility of human A549 lung
carcinoma cells by a recombined vascular basement membrane derived
peptide. Cancer Lett. 292:261–268. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scheer N, Balimane P, Hayward MD, Buechel
S, Kauselmann G and Wolf CR: Generation and characterization of a
novel multidrug resistance protein 2 humanized mouse line. Drug
Metab Dispos. 40:2212–2218. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tiwari AK, Sodani K, Dai CL, et al:
Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-,
ABCG2- and ABCC10-multidrug resistance xenograft models. Cancer
Lett. 328:307–317. 2013. View Article : Google Scholar
|
|
10
|
Laitinen EM, Vaaralahti K, Tommiska J,
Eklund E, Tervaniemi M, Valanne L and Raivio T: Incidence,
phenotypic features and molecular genetics of Kallmann syndrome in
Finland. Orphanet J Rare Dis. 6:412011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shahan TA, Ziaie Z, Pasco S, Fawzi A,
Bellon G, Monboisse JC and Kefalides NA: Identification of
CD47/integrin-associated protein and alpha(v)beta3 as two receptors
for the alpha3(IV) chain of type IV collagen on tumor cells. Cancer
Res. 59:4584–4590. 1999.PubMed/NCBI
|
|
12
|
Huang XW, Wang JY, Li F, Song ZJ, Xie C
and Lu WY: Biochemical characterization of the binding of cyclic
RGDyK to hepatic stellate cells. Biochem Pharmacol. 80:136–143.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang CY, Fong YC, Lee CY, Chen MY, Tsai
HC, Hsu HC and Tang CH: CCL5 increases lung cancer migration via
PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol. 77:794–803.
2009. View Article : Google Scholar
|
|
14
|
Ummanni R, Teller S, Junker H, et al:
Altered expression of tumor protein D52 regulates apoptosis and
migration of prostate cancer cells. FEBS J. 275:5703–5713. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang P, Enomoto A and Takahashi M: Cell
biology of the movement of breast cancer cells: intracellular
signalling and the actin cytoskeleton. Cancer Lett. 284:122–130.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Winograd-Katz SE, Fassler R, Geiger B and
Legate KR: The integrin adhesome: from genes and proteins to human
disease. Nat Rev Mol Cell Biol. 15:273–288. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bouvard D, Pouwels J, De Franceschi N and
Ivaska J: Integrin inactivators: balancing cellular functions in
vitro and in vivo. Nat Rev Mol Cell Biol. 14:430–442. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu P and Luo BH: Integrin bi-directional
signaling across the plasma membrane. J Cell Physiol. 228:306–312.
2013. View Article : Google Scholar
|
|
19
|
Yin B: Focal adhesion kinase as a target
in the treatment of hematological malignancies. Leuk Res.
35:1416–1418. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Riaz A, Ilan N, Vlodavsky I, Li JP and
Johansson S: Characterization of heparanase-induced
phosphatidylinositol 3-kinase-AKT activation and its integrin
dependence. J Biol Chem. 288:12366–12375. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guenther MK, Graab U and Fulda S:
Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK
pathway inhibition in rhabdomyosarcoma. Cancer Lett. 337:200–209.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Choi BH, Kim CG, Lim Y, Shin SY and Lee
YH: Curcumin down-regulates the multidrug-resistance mdr1b gene by
inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett.
259:111–118. 2008. View Article : Google Scholar
|
|
23
|
Goler-Baron V, Sladkevich I and Assaraf
YG: Inhibition of the PI3K-Akt signaling pathway disrupts
ABCG2-rich extracellular vesicles and overcomes multidrug
resistance in breast cancer cells. Biochem Pharmacol. 83:1340–1348.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Konopleva MY, Walter RB, Faderl SH, et al:
Preclinical and early clinical evaluation of the oral AKT
inhibitor, MK-2206, for the treatment of acute myelogenous
leukemia. Clin Cancer Res. 20:2226–2235. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Neri LM, Cani A, Martelli AM, et al:
Targeting the PI3K/ Akt/mTOR signaling pathway in B-precursor acute
lymphoblastic leukemia and its therapeutic potential. Leukemia.
4:739–748. 2014. View Article : Google Scholar
|
|
26
|
Chen KC, Yang TY, Wu CC, et al: Pemetrexed
induces S-phase arrest and apoptosis via a deregulated activation
of Akt signaling pathway. PLoS One. 9:e978882014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang F, Li T, Zhang B, et al:
MicroRNA-19a/b regulates multidrug resistance in human gastric
cancer cells by targeting PTEN. Biochem Biophys Res Commun.
434:688–694. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ning J and Clemmons DR: AMP-activated
protein kinase inhibits IGF-I signaling and protein synthesis in
vascular smooth muscle cells via stimulation of insulin receptor
substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation.
Mol Endocrinol. 24:1218–1229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu L, Dai Y, Chen J, et al: Maelstrom
promotes hepatocellular carcinoma metastasis by inducing
epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail
signaling. Hepatology. 59:531–543. 2014. View Article : Google Scholar
|
|
30
|
Bak Y, Kim H, Kang JW, et al: A synthetic
naringenin derivative, 5-hydroxy-7,4′-diacetyloxyflavanone-N-phenyl
hydrazone (N101–43), induces apoptosis through up-regulation of
Fas/FasL expression and inhibition of PI3K/Akt signaling pathways
in non-small-cell lung cancer cells. J Agric Food Chem.
59:10286–10297. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Krzyzowska M, Shestakov A, Eriksson K and
Chiodi F: Role of Fas/FasL in regulation of inflammation in vaginal
tissue during HSV-2 infection. Cell Death Dis. 2:e1322011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shenoy AR, Kirschnek S and Hacker G: IL-15
regulates Bcl-2 family members Bim and Mcl-1 through JAK/STAT and
PI3K/AKT pathways in T cells. Eur J Immunol. 2500–2507. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bogdal MN, Hat B, Kochanczyk M and
Lipniacki T: Levels of pro-apoptotic regulator Bad and
anti-apoptotic regulator Bcl-xL determine the type of the apoptotic
logic gate. BMC Syst Biol. 7:672013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gravina GL, Marampon F, Giusti I, et al:
Differential effects of PXD101 (belinostat) on androgen-dependent
and androgen-independent prostate cancer models. Int J Oncol.
40:711–720. 2012.
|
|
35
|
Wang TE, Wang YK, Jin J, Xu BL and Chen
XG: A novel derivative of quinazoline, WYK431 induces G2/M phase
arrest and apoptosis in human gastric cancer BGC823 cells through
the PI3K/Akt pathway. Int J Oncol. 45:771–781. 2014.PubMed/NCBI
|
|
36
|
Liu Z, Sun C, Zhang Y, Ji Z and Yang G:
Phosphatidylinositol 3-kinase-C2β inhibits cisplatin-mediated
apoptosis via the Akt pathway in oesophageal squamous cell
carcinoma. J Int Med Res. 39:1319–1332. 2011. View Article : Google Scholar
|
|
37
|
Le Vee M, Jouan E, Stieger B, Lecureur V
and Fardel O: Regulation of drug transporter expression by
oncostatin M in human hepatocytes. Biochem Pharmacol. 82:304–311.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ishikawa T, Wright CD and Ishizuka H: GS-X
pump is functionally overexpressed in cis-diamminedichloroplatinum
(II)-resistant human leukemia HL-60 cells and down-regulated by
cell differentiation. J Biol Chem. 269:29085–29093. 1994.PubMed/NCBI
|
|
39
|
Kibria G, Hatakeyama H and Harashima H:
Cancer multidrug resistance: mechanisms involved and strategies for
circumvention using a drug delivery system. Arch Pharm Res.
37:4–15. 2014. View Article : Google Scholar
|
